The authors propose that Ang-1 and Ang-2 are attractive candidates for a point-of-care test to identify individuals with a risk of progression to severe disease, as they can be incorporated into rapid lateral-flow immunochromatographic tests such as those used in malaria diagnosis. This evidence concerns the gene ANGPT1 and malaria.